{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:48:18Z","timestamp":1757310498001,"version":"3.37.3"},"reference-count":27,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Medications used to treat OUD have common metabolic pathways and pharmacodynamic properties that can lead to drug-drug interactions (DDIs) that may go unnoticed in the inpatient setting. The purpose of this study was to identify the frequency of DDIs between medications prescribed for OUD and commonly used inpatient medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective review of orders for buprenorphine, buprenorphine-naloxone, and methadone to identify potential DDIs. Adult inpatients with an order for one of these medications for OUD were included. Medication regimens were evaluated throughout the inpatient stay and on day of discharge for DDIs. DDIs were classified by severity and type of interaction (increased risk of QT prolongation, additive CNS effects\/respiratory depression, and opioid withdrawal). The primary endpoint was the number of potential DDIs. Other endpoints included number of each classification\/severity of DDI, duration of therapy of interacting medications, and modifications made to OUD medications because of DDIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 102 patients were included, with 215 inpatient interactions and 83 interactions at discharge identified. While inpatient, 85% of patients were on an interacting medication, and 46% of patients were on an interacting medication at discharge. The most common classification of DDI was additive CNS effects\/respiratory depression (68.8% inpatient, 50.6% discharge), followed by QT prolongation (24.2% inpatient, 45.8% discharge). The majority of DDIs were classified as requiring close monitoring rather than contraindicated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>There are opportunities to optimize the prescribing practices surrounding OUD medications in both the inpatient setting and at discharge to ensure patient safety.<\/jats:p><\/jats:sec>","DOI":"10.9740\/mhc.2021.07.231","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T17:41:00Z","timestamp":1626457260000},"page":"231-237","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of drug-drug interactions in hospitalized patients on medications for OUD"],"prefix":"10.9740","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2123-3124","authenticated-orcid":true,"given":"Olivia","family":"Berger","sequence":"first","affiliation":[{"name":"Pain Management and Palliative Care PGY-2 Pharmacy Resident, The Johns Hopkins Hospital, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4683-7802","authenticated-orcid":true,"given":"Katherine","family":"Rector","sequence":"additional","affiliation":[{"name":"Clinical Team Leader, Internal Medicine, Atrium Health's Carolinas Medical Center, Charlotte, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6549","authenticated-orcid":true,"given":"Jacqueline","family":"Meredith","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist, Infectious Diseases, Clinical Team Leader, Antimicrobial Stewardship (Central Division), Atrium Health's Carolinas Medical Center, Charlotte, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-6514","authenticated-orcid":true,"given":"Jamielynn","family":"Sebaaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"2021071617405397300_i2168-9709-11-4-231-b01","doi-asserted-by":"crossref","unstructured":"McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010; 19(1): 4- 16. DOI: 10.1111\/j.1521-0391.2009.00005.x. PubMed PMID: 20132117; PubMed Central PMCID: PMC3334287.","DOI":"10.1111\/j.1521-0391.2009.00005.x"},{"key":"2021071617405397300_i2168-9709-11-4-231-b02","doi-asserted-by":"crossref","unstructured":"Lee H-Y, Li J-H, Wu L-T, Wu J-S, Yen C-F, Tang H-P. Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy. 2012; 7: 11. DOI: 10.1186\/1747-597X-7-11. PubMed PMID: 22429858; PubMed Central PMCID: PMC3373376.","DOI":"10.1186\/1747-597X-7-11"},{"key":"2021071617405397300_i2168-9709-11-4-231-b03","unstructured":"Palleria C, Di Paolo A, Giofr\u00e8 C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013; 18(7): 601- 10. PubMed PMID: 24516494."},{"key":"2021071617405397300_i2168-9709-11-4-231-b04","unstructured":"Dolophine\u00ae [package insert]. Columbus (OH): Roxane Laboratories; c2006."},{"key":"2021071617405397300_i2168-9709-11-4-231-b05","unstructured":"Suboxone\u00ae [package insert]. Warren (NJ): Aquestive Therapeutics; c2019."},{"key":"2021071617405397300_i2168-9709-11-4-231-b06","unstructured":"Subutex\u00ae [package insert]. Hull (UK): Reckitt Benckiser Healthcare; c2011."},{"key":"2021071617405397300_i2168-9709-11-4-231-b07","doi-asserted-by":"crossref","unstructured":"Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garc\u00eda de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005; 100(7): 981- 9. DOI: 10.1111\/j.1360-0443.2005.01089.x. PubMed PMID: 15955014.","DOI":"10.1111\/j.1360-0443.2005.01089.x"},{"key":"#cr-split#-2021071617405397300_i2168-9709-11-4-231-b08.1","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. Department of Health and Human Services [updated 2019 Dec 18"},{"key":"#cr-split#-2021071617405397300_i2168-9709-11-4-231-b08.2","unstructured":"cited 2021 Jun 18]. Available from: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"2021071617405397300_i2168-9709-11-4-231-b09","unstructured":"Drug Interactions [Internet]. Ann Arbor (MI): Truven Health Analytics, Inc; c2019[updated 2021 Jun 8; cited 2021 Jun 18].Available from: https:\/\/www.micromedexsolutions.com\/home\/dispatch"},{"key":"2021071617405397300_i2168-9709-11-4-231-b10","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain \u2013 United States, 2016. MMWR Recomm Rep. 2016; 65(1): 1- 49. DOI: 10.15585\/mmwr.rr6501e1. PubMed PMID: 26987082.","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"2021071617405397300_i2168-9709-11-4-231-b11","doi-asserted-by":"crossref","unstructured":"Sebaaly J, Parsons LB, Pilch NAW, Bullington W, Hayes GL, Easterling H. Clinical and financial impact of pharmacist involvement in discharge medication reconciliation at an academic medical center: a prospective pilot study. Hosp Pharm. 2015; 50(6): 505- 13. DOI: 10.1310\/hpj5006-505. PubMed PMID: 26405342.","DOI":"10.1310\/hpj5006-505"},{"key":"2021071617405397300_i2168-9709-11-4-231-b12","doi-asserted-by":"crossref","unstructured":"Newman D, Haight R, Hoeft D. Implementation and impact of pharmacists led medication reconciliation and patient education at discharge from an inpatient behavior health unit. Ment Health Clin [Internet]. 2013; 3(1): 96.","DOI":"10.9740\/mhc.n161412"},{"key":"2021071617405397300_i2168-9709-11-4-231-b13","doi-asserted-by":"crossref","unstructured":"Jack BW. A reengineered hospital discharge program to decrease rehospitalization. Ann Intern Med. 2009; 150(3): 178. DOI: 10.7326\/0003-4819-150-3-200902030-00007. PubMed PMID: 19189907.","DOI":"10.7326\/0003-4819-150-3-200902030-00007"},{"key":"2021071617405397300_i2168-9709-11-4-231-b14","doi-asserted-by":"crossref","unstructured":"Kilcup M, Schultz D, Carlson J, Wilson B. Postdischarge pharmacist medication reconciliation: Impact on readmission rates and financial savings. J Am Pharm Assoc (2003). 2013; 53(1): 78- 84. DOI: 10.1331\/JAPhA.2013.11250. PubMed PMID: 23636160.","DOI":"10.1331\/JAPhA.2013.11250"},{"key":"2021071617405397300_i2168-9709-11-4-231-b15","doi-asserted-by":"crossref","unstructured":"Phatak A, Prusi R, Ward B, Hansen LO, Williams MV, Vetter E, et al. Impact of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation, medication education, and postdischarge call-backs (IPITCH Study). J Hosp Med. 2016; 11(1): 39- 44. DOI: 10.1002\/jhm.2493. PubMed PMID: 26434752.","DOI":"10.1002\/jhm.2493"},{"key":"2021071617405397300_i2168-9709-11-4-231-b16","unstructured":"Najafzadeh M, Schnipper JL, Shrank WH, Kymes S, Brennan TA, Choudhry NK. Economic value of pharmacist-led medication reconciliation for reducing medication errors after hospital discharge. Am J Manag Care. 2016; 22(10): 654- 61. PubMed PMID: 28557517."},{"key":"2021071617405397300_i2168-9709-11-4-231-b17","doi-asserted-by":"crossref","unstructured":"Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther. 2002; 23(6): 403- 16. DOI: 10.1046\/j.1365-2710.1998.00086.x. PubMed PMID: 10048501.","DOI":"10.1046\/j.1365-2710.1998.00086.x"},{"key":"2021071617405397300_i2168-9709-11-4-231-b18","doi-asserted-by":"crossref","unstructured":"Punyawudho B, Cloyd JC, Leppik IE, Ramsay RE, Marino SE, Pennell PB, et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet. 2009; 48(5): 313- 20. DOI: 10.2165\/00003088-200948050-00003. PubMed PMID: 19566114; PubMed Central PMCID: PMC2945813.","DOI":"10.2165\/00003088-200948050-00003"},{"key":"2021071617405397300_i2168-9709-11-4-231-b19","doi-asserted-by":"crossref","unstructured":"Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011; 89(2): 234- 42. DOI: 10.1038\/clpt.2010.271. PubMed PMID: 21191377.","DOI":"10.1038\/clpt.2010.271"},{"key":"2021071617405397300_i2168-9709-11-4-231-b20","doi-asserted-by":"crossref","unstructured":"Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001; 41: 535- 67. DOI: 10.1146\/annurev.pharmtox.41.1.535. PubMed PMID: 11264468.","DOI":"10.1146\/annurev.pharmtox.41.1.535"},{"key":"2021071617405397300_i2168-9709-11-4-231-b21","doi-asserted-by":"crossref","unstructured":"Daniel NM, Walsh K, Leach H, Stummer L. Implementation of a QTc-interval monitoring protocol by pharmacists to decrease cardiac risk in at-risk patients in an acute care inpatient psychiatric facility. Ment Health Clin [Internet]. 2019; 9(2): 82- 7. DOI: 10.9740\/mhc.2019.03.082. PubMed PMID: 30842915; PubMed Central PMCID: PMC6398356.","DOI":"10.9740\/mhc.2019.03.082"},{"key":"2021071617405397300_i2168-9709-11-4-231-b22","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives[Internet].Washington: National Academies Press; c2019[updated 2019 Mar 30; cited 2019 Aug 19].Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538936\/."},{"key":"2021071617405397300_i2168-9709-11-4-231-b23","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550.DOI: 10.1136\/bmj.j1550. PubMed PMID: 28446428; PubMed Central PMCID: PMC5421454.","DOI":"10.1136\/bmj.j1550"},{"key":"2021071617405397300_i2168-9709-11-4-231-b24","doi-asserted-by":"crossref","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015; 105(8): e55- 63. DOI: 10.2105\/AJPH.2015.302664. PubMed PMID: 26066931; PubMed Central PMCID: PMC4504312.","DOI":"10.2105\/AJPH.2015.302664"},{"key":"2021071617405397300_i2168-9709-11-4-231-b25","doi-asserted-by":"crossref","unstructured":"Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2020; 108(1): 55- 64. DOI: 10.1016\/j.jsat.2019.06.015. PubMed PMID: 31277891.","DOI":"10.1016\/j.jsat.2019.06.015"},{"key":"2021071617405397300_i2168-9709-11-4-231-b26","doi-asserted-by":"crossref","unstructured":"Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarett JB, Ottney AR, et al. Mobilizing pharmacists to address the opioid crisis: a joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 2020; 3(8): 1493- 513.","DOI":"10.1002\/jac5.1331"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/4\/231\/2868677\/i2168-9709-11-4-231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/4\/231\/2868677\/i2168-9709-11-4-231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:40Z","timestamp":1731687820000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/11\/4\/article-p231.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,7,16]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2021.07.231","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}